Component

TAAR1 receptor activation assay

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Trace-amine receptor experiments support beta-phenylethylamine-responsive receptor signaling.

    Beta-Phenylethylamine / PEA → TAAR1 receptor activation assay Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary indexed abstract and bibliographic record; full experimental methods not independently extracted.
    experimental_model
    Cloned mammalian GPCR systems; primary abstract, exact species-specific potency not extracted.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    No inference of oral Phe brain benefit or chocolate effects.
    nutrient_topic
    L-Phenylalanine collection; chapter membership is not a causal effect. · L-Phenylalanine
    plain_language
    Trace-amine receptor experiments support beta-phenylethylamine-responsive receptor signaling.
    primary_references
    Trace amines: identification of a family of mammalian G protein-coupled receptors. | 2001 | DOI 10.1073/pnas.151105198 | PMID 11459929 | https://pubmed.ncbi.nlm.nih.gov/11459929/ | https://doi.org/10.1073/pnas.151105198
    source_locator
    Reviewed reference lines 171-179; exact primary location described in quoted passage where extracted.

    L-Phenylalanine: detailed mechanisms of action (reviewed 5 October 2026) · lines 171–179

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Cloned mammalian GPCR systems; primary abstract, exact species-specific potency not extracted. · Recorded from source · Recorded from source

    <!-- section:trace-and-d --> Trace-amine receptor cloning experiments showed activation/binding by biogenic amines including beta-phenylethylamine, supporting a receptor branch downstream of amino-acid decarboxylation. They do not demonstrate that oral Phe increases useful human brain signaling, that chocolate works through this route, or a universal half-life for PEA. MAO inhibition, tyramine exposure and Phe precursor supply are distinct conditions. In a 1981 tracer report, one healthy woman received 8 mg/kg labeled D- or L-Phe. Labeled Tyr and protein-bound Phe appeared after either isomer; D-derived Phe appeared more prominently and cleared more slowly. This disproves absolute metabolic inertness of D-Phe but does not show that ribosomes directly incorporate D-Phe, identify a single human racemase, or establish equivalent nutrition across populations. A 30-person chronic-pain crossover trial comparing D-Phe 250 mg four times daily for four weeks with placebo did not show analgesic superiority. Proposed enkephalin preservation is not verified by that trial, and carboxypeptidase A is not neprilysin. A separate 20-person 150 mg/kg tyrosine study reported a selective working-memory benefit during multitasking with other task nulls; that is tyrosine evidence, not a phenylalanine efficacy trial. Sources: [Trace amines: identification of a family of mammalian G protein-coupled receptors](https://pubmed.ncbi.nlm.nih.gov/11459929/); [Studies on phenylalanine metabolism by tracer techniques. IV. Biotransformation of D- and L-phenylalanine in man](https://pubmed.ncbi.nlm.nih.gov/7273250/); [Analgesic effectiveness of D-phenylalanine in chronic pain patients](https://pubmed.ncbi.nlm.nih.gov/3524509/); [Tyrosine improves working memory in a multitasking environment](https://pubmed.ncbi.nlm.nih.gov/10548261/) <!-- end:trace-and-d -->
    Complete structured claim and evidence

  2. Modafinil did not directly activate TAAR1 but changed phenethylamine responses with particular coexpressed transporters.

    Modafinil → TAAR1 receptor activation assay Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary indexed abstract checked; full methods and figures not comprehensively reviewed.
    experimental_contrast
    {"intervention": "Modafinil alone or with phenethylamine/transporter coexpression", "comparator": "Corresponding receptor-only/ligand controls", "endpoint": "Modafinil did not directly activate TAAR1 but changed phenethylamine responses with particular coexpressed transporters.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Receptor/transporter coexpression assays; direct agonism separated from transporter-dependent modulation.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    Modafinil did not directly activate TAAR1 but changed phenethylamine responses with particular coexpressed transporters.
    primary_references
    Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. | 2006 | DOI 10.1124/jpet.106.106583 | PMID 16885432 | https://pubmed.ncbi.nlm.nih.gov/16885432/
    source_locator
    Reviewed reference lines 85-85; exact primary location described in quoted passage where extracted.

    Modafinil: detailed mechanisms of action (reviewed 3 October 2026) · lines 85–85

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Receptor/transporter coexpression assays; direct agonism separated from transporter-dependent modulation. · Recorded from source · Recorded from source

    A rhesus-monkey PET study detected both DAT and NET occupancy after intravenous modafinil. In human-transporter cell assays, dopamine uptake was inhibited more potently than norepinephrine uptake; serotonin uptake inhibition was much weaker. The same work found no direct TAAR1 activation, but altered phenethylamine responses when TAAR1 was coexpressed with particular transporters. This distinguishes **direct receptor agonism from transporter-dependent modulation**. Monkey intravenous target engagement does not establish the contribution of human NET at oral therapeutic exposure. [Madras et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16885432/)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.